trial

Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment

NCTId NCT00707382
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 311 (actual)
Sponsored by Gesche Jurgens
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
311 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-02
Primary completion
2011-12
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
(1) Genotyping for CYP4502D6 and 2C19 polymorphisms(2) Intense clinical monitoring

Sponsors

Gesche JurgensLead Sponsor
Bispebjerg HospitalCollaborator
Research Unit, Psyciatric Centre BispebjergCollaborator
Research Institute of Biological Psychiatry,Psychiatric Centre Sct. HansCollaborator
Danish Centre for Health Technology AssessmentCollaborator
The Ministry of Health and Prevention, DenmarkCollaborator
TrygFonden, DenmarkCollaborator

Investigators

1
Gesche Jürgens, MD, phdPrincipal Investigator

Sites

1 total
Copenhagen, Denmark

Facts & assertions

4 sourced
Enrollment
311
Phase
NA
Primary Completion Date
2011-12
Status
COMPLETED
relationships
The graph out of here
drug
(1) Genotyping for CYP4502D6 and 2C19 polymorphisms
drug
(2) Intense clinical monitoring
drug
lead_sponsor
Gesche Jurgens
company
collaborator
Bispebjerg Hospital
company
Research Unit, Psyciatric Centre Bispebjerg
company
indication
Schizophrenia
indication
Schizophrenia
indication
Patient Compliance
indication
investigator
Gesche Jürgens, MD, phd
person